EichorEICHOR
Study identifier: NCT07360899 Synced from ClinicalTrials.gov · August 04, 2026
● Recruiting

Atrial Fibrillation TRIal of Left Atrial Appendage Closure Using Seralene Hemostatic Suture

Condition: ATRIAL APPENDAGE CLOSURE for ATRIAL FIBRILLATION · Atrial Fibrillation (AF) · Mitral Valve Surgery  ·  Sponsor: Institute of Cardiovascular Diseases, Vojvodina

PhaseNA
Planned participants200
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Atrial fibrillation is a common heart rhythm disorder that increases the risk of stroke. In patients with atrial fibrillation, blood clots most often form in a small structure of the heart called the left atrial appendage. If a blood clot travels from the heart to the brain, it can cause a stroke. Blood-thinning medications are commonly prescribed to reduce the risk of stroke in patients with atrial fibrillation. However, some patients cannot take these medications long-term because of bleeding risk, side effects, or other medical reasons. Closing the left atrial appendage is an alternative approach to reduce the risk of stroke by preventing blood from collecting in this area. When patients undergo cardiac surgery for another indication, closure of the left atrial appendage can be performed during the same operation. This study is designed to evaluate the safety and effectiveness of surgical closure of the left atrial appendage using a device called AtriLASH during cardiac surgery. AtriLASH is a surgical suture-based device intended to close the left atrial appendage. The study will assess whether the left atrial appendage can be safely and effectively closed using this method in patients with atrial fibrillation undergoing cardiac surgery. The information obtained from this study may help determine whether this approach can reduce the risk of stroke and potentially decrease the need for long-term use of blood-thinning medications in selected patients.

This description comes directly from the study's public registry record.

Talk to the study team

Lazar Velicki, MD, PhD  ·  +381 21 4805701  ·  lazar.velicki@ikvbv.ns.ac.rs

Milos Matkovic, MD,PhD  ·  dr.matko@hotmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Institute of cardiovascular diseases VojvodinaKamenitz, Vojvodina, SerbiaRecruiting

Follow this study

Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.

We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →